Latest news with #Enterogermina
Tahya Masr
06-05-2025
- Business
- Tahya Masr
Opella launches as an independent company to redefine the future of self-care
It is official: Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of Opella, Sanofi keeping a significant shareholding with a 48.2% stake and Bpifrance owning a 1.8% stake. Opella is stepping into its next chapter with powerful backing, and a clear mission - 'Health in Your Hands' - making self-care as simple as it should be. This is not just a change of ownership. This is a bold move. As the third-largest global player in the €190 billion Over-The-Counter and Vitamins, Minerals and Supplements space, Opella starts a new journey in one of the most dynamic, resilient corners of healthcare – where megatrends like aging populations, digital access, and self-care demand are rewriting the rulebook. Opella is headquartered in France but thinks global. Its 100 brands – including Telfast, Doliprane, Bronchicum, Enterogermina, Maalox, Nasacort, Maxilase, Bisolvon and Buscopan – are already trusted names in homes around the world. The self-care environment is still far too complex, leaving most people who suffer without treatment. Opella is grounded in science, with deep consumer obsession and a commitment to sustainability, to offer solutions that help people access the care they deserve. Julie Van Ongevalle, Opella President and CEO: 'Going independent is not just a milestone. It is our moment. I am proud of our talented team of 11,000 who made this happen. With the right partners and a sharp focus, we are set to reshape how people everywhere manage their health – simply, confidently, and on their terms.' Feirouz Ellouze, General Manager of Opella AMET Zone (Africa-Middle East-Türkiye) 'At Opella, our mission is to simplify self-care, making it as simple as it should be. We work together with all our stakeholders to enhance health literacy and extend our vision of 'health in your hands'. This new chapter at Opella is dedicated to advancing our journey towards becoming fast-moving consumer healthcare company globally. We firmly believe in our people and their ability to create a lasting legacy in the countries where we operate.' David Taylor takes on the role of Chairman of Opella's Supervisory Board. Former Chairman and CEO of Procter & Gamble, and current Chairman of the Board of Delta and Senior Advisor to CD&R funds, David brings decades of brand experience, people-first leadership, and a deep belief in doing things better. David Taylor, Chairman of Opella's Supervisory Board: 'What drew me to Opella is a mission with meaning, a company with courage, a talented team, and a business ready to break new ground. Opella is not here to tweak the system – but to reimagine it.' The priority is clear: strengthen trusted brands and deepen presence in key markets. The possibilities are endless – from prescription to over-the-counter switches to smart acquisitions and geographic expansion. This is more than independence. It is the freedom to act. The power to simplify. And the drive to redefine the future of self-care.
Mid East Info
05-05-2025
- Business
- Mid East Info
Opella launches as an independent company to redefine the future of self-care. - Middle East Business News and Information
UAE, May 2025 – It is official: Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of Opella, Sanofi keeping a significant shareholding with a 48.2% stake and Bpifrance owning a 1.8% stake. Opella is stepping into its next chapter with powerful backing, and a clear mission – 'Health in Your Hands' – making self-care as simple as it should be. This is not just a change of ownership. This is a bold move. As the third-largest global player in the €190 billion Over-The-Counter and Vitamins, Minerals and Supplements space, Opella starts a new journey in one of the most dynamic, resilient corners of healthcare – where megatrends like aging populations, digital access, and self-care demand are rewriting the rulebook. Opella is headquartered in France but thinks global. Its 100 brands – including Telfast , Enterogermina, Dulcolax, Maalox, Buscopan ,Mucosolvan , Bronchicum ,Naselfast and Pharmaton– are already trusted names in homes around the world. The self-care environment is still far too complex, leaving most people who suffer without treatment. Opella is grounded in science, with deep consumer obsession and a commitment to sustainability, to offer solutions that help people access the care they deserve. Julie Van Ongevalle, Opella President and CEO: 'Going independent is not just a milestone. It is our moment. I am proud of our talented team of 11,000 who made this happen. With the right partners and a sharp focus, we are set to reshape how people everywhere manage their health – simply, confidently, and on their terms.' Feirouz Ellouze, General Manager of Opella AMET Zone (Africa-Middle East-Türkiye) 'At Opella, our mission is to simplify self-care, making it as simple as it should be. We work together with all our stakeholders to enhance health literacy and extend our vision of 'health in your hands'. This new chapter at Opella is dedicated to advancing our journey towards becoming fast-moving consumer healthcare company globally. We firmly believe in our people and their ability to create a lasting legacy in the countries where we operate.' David Taylor takes on the role of Chairman of Opella's Supervisory Board. Former Chairman and CEO of Procter & Gamble, and current Chairman of the Board of Delta and Senior Advisor to CD&R funds, David brings decades of brand experience, people-first leadership, and a deep belief in doing things better. David Taylor, Chairman of Opella's Supervisory Board: 'What drew me to Opella is a mission with meaning, a company with courage, a talented team, and a business ready to break new ground. Opella is not here to tweak the system – but to reimagine it.' The priority is clear: strengthen trusted brands and deepen presence in key markets. The possibilities are endless – from prescription to over-the-counter switches to smart acquisitions and geographic expansion. This is more than independence. It is the freedom to act. The power to simplify. And the drive to redefine the future of self-care. About Opella. Opella is the self-care challenger with the third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people's hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world's most loved brands, including Telfast , Enterogermina, Dulcolax, Maalox, Buscopan ,Mucosolvan , Bronchicum ,Naselfast, Pharmaton. B Corp certified in multiple markets, we are active players in the journey towards healthier people and planet.
Campaign ME
29-04-2025
- Health
- Campaign ME
Enterogermina Anti-Murphy's Law Toast mockumentary tests ‘the 5-second rule'
Enterogermina – a client of McCann Health UAE and a non-prescriptive probiotic brand that helps to restore and reinstate gut health – has launched The Anti-Murphy's Law Toast campaign in the form of a mockumentary that challenges the '5-second rule' through 'specially engineered toast'. Through the campaign, which is being rolled out on digital and social channels in the UAE, the brand challenges Murphy's Law which states that 'anything that can go wrong, will go wrong' and invites people to question the myth: is it acceptable to eat something that has fallen on the ground, even if it's for less than five seconds? The campaign was brought to life for Opella Enterogermina by MRM Spain, digital agency Cappuccino, production company Cariño Contents, with the 360° media strategy led by WMcCANN, including a documentary premiere on Discovery Channel. Initially launched in Brazil, more than 40 key opinion leaders (KOLs) attended an exclusive screening of the documentary at Sao Paolo's famous Le Pain Quotidien bakery. The campaign also featured influencer amplification in partnership with Spark and a digital strategy led by Monks, focusing on social media engagement. Rollout of The Anti-Murphy's Law Toast campaign Created by MRM Spain, the campaign saw Enterogermina collaborate with physicist Robert Matthews, who was awarded the Ig Nobel Prize in 1996 for his study proving Murphy's Law applied to toast. A short documentary was created as part of the campaign, showing Matthews working with a team of scientists and bakers to design a specially engineered toast, in an attempt to defy this theory. The short film dives into the scientific research behind the concept, the creation of the first prototypes in the kitchen of 12 Michelin-starred chef Nuño García, and features insights from microbiology researcher Simon Baines. Ségolène de Marsac, Global Brand GM at Enterogermina, said, 'This innovative activation embodies our commitment to turning conventional wisdom on its head. Just as we are challenging the laws of gravity, we are also challenging common misconceptions about gut health through this unexpected mockumentary.' The prototype was a success, landing butter-side up about 75 per cent of the time, as opposed to only 37 per cent of the time when using conventional toast. 'By questioning a widely held belief like the 5-second rule or the odds of toast landing butter-side up, we aim to spark curiosity and discussions about gut health in a light-hearted way,' says Eduardo Magalhães, CMO of Opella Brasil. Félix del Valle, MRM Spain CCO, concluded, 'Thanks to the entire team at Opella and Enterogermina for supporting such a bold and brave project. This initiative takes a truly different approach to start a conversation about gut health. The result is a unique content that grabs your attention from the very first second, combining pure entertainment with education.' CREDITS: Client: Opella-Enterogermina Alberto Hernandez, Valerie Brass, Julie Regis, Segolene De-Marsac, Michele Gatti, Eugenie Cornuet, Rafael Masunari, Jaqueline Gimenes, Nadia Borges Depieri, Veronika Rodrigues, Débora Bassanezi, Eduardo Magalhães, Paolla Minotelli, Agnes Motta, Carolina Frateschi, Marcelo Tuma, Giovanna Araujo, Jéssica Canette, Thamiris Tavares, Diego Coelho e Juliana Mineoka. EVP Global Business Lead: Nicolas Guzman Global Business Director: Álvaro Cuneo Agency: MRM Spain MRM Global CCO: Ronald Ng MRM Global Opella CCO & MRM Spain CCO: Félix del Valle Executive Creative Director: Guillermo Santaisabel Creative Director: Gui Moreira Associate Creative Directors: Fernando Morate, Sergio García Copywriter: Carmen Bello Art Director: Javier García 3D Artist/Art Director: Daniel Oteiza Design Director: Pablo Camarero Visual Designers: Celia López, Paula Batista Digital Project Manager: Miguel Simón Website developer: Jaime García Gobal Opella CSO: Clément Fiorda, Strategic planner: Julieta Pesci Global Business Leader & Head of Growth: Stefano Piccini Business Leader: Patricia Burelli Account Director: Lucía Pereira Account Supervisor: María Nuñez Business Affairs: Coral Sellares, América Almodóvar PR Agency: Weber Shandwick Brazil Associate: Rhaisa Trombini Account Manager: Aline Corrêa Account Director: Bruna Rassi Consumer & Healthcare Practices Vice President: Laura Chiavenato Digital Agency: Cappuccino CCO: Vitor Elman Creative Director: Diego Torres VP Operations: Lara Magalhães CBO: Rodrigo Martinez Local Agency: WMcCann / Brasil Head of Content: Karoline Canin Contenido: Caroline Sacute Business Director: Thiago Xavier Account: Carolina Rissotti Media: Luccas Athayde, Rogerio Jorge, Victor Takekawa e Luciana Miranda Head de Producción: Daniela Toda Integrated Production: Fernanda Pinheiro Production: Nereu Marinho PR: Kerena Neves e Giulia Camargo
